Boult Wade Tennant
UPC » Austria brings the UPC a step closer

We’ve known for a while that the Unified Patent Court (UPC) was getting closer to becoming a reality after a very bumpy road, but I am excited to see that is now starting to look like it will be with us sooner rather than later!

Last week, Austria finalised the parliamentary ratification procedure relating to the “PAP-Protocol”. This Protocol is secondary legislation relating to a Provisional Application Phase (PAP) of the UPC which will enable last preparations to be made before the UPC opens its doors (e.g. appointing judges and other staff, and finalising the case management IT system). Now, Austria simply needs to deposit their ratification instrument for the Provisional Application Phase to begin with immediate effect. It seems likely that this will happen in the next few weeks, with the UPC likely to become fully operational later in 2022, or in early 2023.

Now is definitely the time for everyone to start re-familiarising themselves with the relevant UPC and Unitary Patent legislation. For example, do you initially want to “opt out” your European patents from the jurisdiction of the UPC? Are you interesting in obtaining Unitary Patents in future? We will be working with our clients on these and other issues in the coming months.

On 2 December 2021, the Austrian Parliament successfully completed the ratification of the Protocol to the Agreement on a Unified Patent Court on provisional application (PPA). This is another very important step towards the start of the new system.

https://www.epo.org/news-events/news/2021/20211203a.html

Relevant sectors
Food and beverage
  • Nutrition
  • Retail
  • Beverages
Artificial intelligence and machine learning
Consumer goods and retail
  • Anti-counterfeit devices
  • Moda
  • Health, fitness and sport
  • Beauty
  • Fashion
  • Luxury goods
  • Retail
  • Household goods
Trade marks
  • Mechanical products
  • Services
  • Telecommunications
  • Financial services
  • Cosmetics and perfumery
  • Consumer goods
Chemicals
  • Agrochemicals
  • Catalysts
  • Dispersions and colloids
  • Lubricants
  • Polymers and plastics
Materials
  • Advanced materials
  • Composite materials
  • Metallurgy and alloys
  • Nanotechnology
Industrial manufacturing and processing
  • Packaging
  • Polymers and plastics
  • Printing tech
  • Additive manufacturing
  • Coatings
  • Construction
Electronics and electrical devices
  • Restaurants and bars
  • Travel and leisure
  • Testing systems, control systems, signal processing
  • Computer and IT architecture and system design
  • Medical devices
  • Optics
  • Robotics
  • Scientific instruments
  • Semiconductor devices
  • Wearable tech and human interfaces
Communications and networks
  • Oceanography, marine
  • Cloud computing
  • Internet of things (IOT)
  • Wired and wireless networks
Energy and green technologies
  • Solar power
  • Wind turbines
  • Water, oil and gas, nuclear, fusion, fission
  • Clean air
  • Fuel cells and battery technology
  • Renewables and recycling
  • Biofuels
Automotive
  • Autonomous vehicles
  • Electric vehicles
  • Engines
Aerospace
  • Commercial aviation
  • Defence and security
  • Space and satellites
  • Unmanned aerial vehicles
Pharmaceuticals
  • Pharmaceuticalsceutical formulations
  • Diagnostics
  • Drug delivery
  • Generic market entry
  • Medicinal chemistry
  • Methods of production and synthesis
  • Personalised medicine/disease biomarkers
  • Pharmaceutical formulations
  • Polymorphs
  • Small molecule pharmaceuticals
  • Supplementary protection certificates (SPCs)
Biotechnology
  • Bioinformatics
  • Next generation sequencing
  • Women’s health products
  • Vaccinology (e.g. viral vectors; mRNA vaccines)
  • Therapeutic antibodies
  • Synthetic biology
  • Stem cell therapies
  • Recombinant protein production and purification
  • Personalised medicine/disease biomarkers
  • Nucleic acid synthesis
  • Supplementary protection certificates (SPCs)
  • Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
  • GM crops
  • Genomic and molecular tools and methods
  • Gene editing (e.g. CRISPR)
  • Drug delivery
  • Biosimilars
  • Antibody manufacture and formulation
  • Antibody engineering
Medical devices and diagnostics 
  • Immuno-oncology
  • Artificial intelligence
  • Devices
  • Diagnostic instruments
  • Digital health
  • Drug delivery
  • In vitro diagnostics
  • Medtech
Computing and software
  • Digital assistants, virtual assistants and software agents
  • Multimedia, audio/video processing and animation
  • Metaverse, virtual reality (VR) and augmented reality (AR)
  • Data management and storage, databases and data compression
  • Data and software security, cryptography and digital rights management (DRM)
  • Software applications and systems, mobile applications, user interfaces
  • Natural language processing
  • Search engines
  • Robotic process automation
  • Quantum computing
  • Motor capture
  • Machine vision
  • Fintech and adtech
  • Computer games
  • Communications and networks
  • Blockchain and distributed ledgers
  • Bioinformatics
  • Signal processing
  • Artificial intelligence and machine learning